Compare ARTNA & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARTNA | AURA |
|---|---|---|
| Founded | 1905 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.0M | 396.8M |
| IPO Year | 1996 | 2021 |
| Metric | ARTNA | AURA |
|---|---|---|
| Price | $31.92 | $6.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.20 |
| AVG Volume (30 Days) | 24.6K | ★ 194.6K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | ★ 12.02 | N/A |
| EPS | ★ 2.18 | N/A |
| Revenue | ★ $111,776,000.00 | N/A |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | $14.66 | ★ N/A |
| Revenue Growth | ★ 5.80 | N/A |
| 52 Week Low | $29.45 | $4.35 |
| 52 Week High | $36.19 | $9.04 |
| Indicator | ARTNA | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 56.27 |
| Support Level | $30.89 | $6.27 |
| Resistance Level | $31.70 | $6.69 |
| Average True Range (ATR) | 0.60 | 0.30 |
| MACD | 0.15 | 0.04 |
| Stochastic Oscillator | 88.95 | 71.12 |
Artesian Resources Corp operates as a holding company with a focus on water distribution and wastewater services. Its regulated utility segment includes subsidiaries providing water and wastewater services in Delaware, Maryland, and Pennsylvania. Water distribution spans residential, commercial, industrial, and municipal sectors, while wastewater services are offered in Sussex County, Delaware. The company also engages in non-utility businesses, offering service line protection plans, engineering services, and contract operations for water and wastewater systems. The regulated utility segment constitutes the portion of the company's operations, subject to regulations by Delaware, Maryland, and Pennsylvania.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.